Guideline concordant therapy was shown to improve OS for NSCLC (Ahmed et al. 2017) and for breast cancer patients in general (Wöckel et al. 2010; Wolters et al. 2015), as well as for specific subtypes like Her2-positive breast cancer and triple-negative breast cancer (Schwentner et al. 2012; Inwald et al. 2014) and recommended adjuvant radiotherapy and chemotherapy (Wimmer et al. 2019; Taubenhansl et al. 2020). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.